CorMedix Q3 revenue slumps to $54.5M, announces Heron asset acquisition, narrows EBITDA guidance

What happened

CorMedix reported Q3 2026 results with consolidated revenue of $54.5 million, a net loss of $14.7 million, and adjusted EBITDA of $3.1 million, while also announcing the acquisition of Heron Therapeutics' assets. This follows the company's previously communicated expectation that the TDAPA reimbursement step-down on July 1, 2026 would pressure DefenCath pricing and revenue in the second half of the year. The quarterly revenue figure is substantially below the company's earlier full-year revenue guidance of $300–$320 million, indicating that the post-TDAPA revenue decline has been more severe than initially modeled, though the company maintains its revenue guidance and narrows adjusted EBITDA guidance. The acquisition of Heron Therapeutics assets represents a strategic move to further diversify the product portfolio beyond DefenCath and the Melinta portfolio, likely aimed at offsetting the DefenCath revenue erosion and adding new growth avenues. With adjusted EBITDA barely positive and a net loss, profitability has deteriorated sharply from 2025 levels, underscoring the challenge of the reimbursement transition and the critical importance of the Heron acquisition in stabilizing operations.

Implication

The Q3 revenue miss and low adjusted EBITDA indicate that the DefenCath pricing reset is biting harder than modeled, and prior estimates of FY2026 revenue near $300 million may be too optimistic. The Heron acquisition adds a new product line, but integration risk is high, and the company is now navigating two acquisitions in one year, which could strain management and cash flow. The maintained revenue guidance may rely on Heron contributions, but the quality of that revenue and its margin profile need scrutiny. Investors should focus on upcoming disclosures about Heron's assets, synergy plans, and updated guidance for Q4 and 2027. The thesis has shifted from a DefenCath utilization story to a diversified pharma roll-up story, with lower near-term certainty.

Thesis delta

The original thesis held that CRMD was undervalued because the market overestimated the impact of the TDAPA step-down on DefenCath, with potential re-rating from KPI disclosure and REZZAYO data. However, Q3 2026 results show a sharper revenue decline and weaker profitability than expected, indicating the step-down impact was underestimated. The acquisition of Heron assets signals a shift from organic DefenCath growth to inorganic diversification, making the investment case contingent on successful integration and synergy realization rather than DefenCath's standalone performance.